Create
Log in
Sign up
Golden has been acquired by ComplyAdvantage.
Read about it here ⟶
US Patent 11692024 Methods of treating AL amyloidosis
Overview
Structured Data
Issues
Contributors
Activity
All edits
Edits on 5 Jul, 2023
"Created via: Entity Importer"
Golden AI
created this topic on 5 Jul, 2023
Edits made to:
Infobox
(
+20
properties)
Article
(
+87
characters)
US Patent 11692024 Methods of treating AL amyloidosis
Article
Antibody formulations and methods useful for treatment of patients with AL amyloidosis.
Infobox
Is a
Patent
0
Patent Jurisdiction
United States Patent and Trademark Office
0
Patent Number
11692024
0
Date of Patent
July 4, 2023
0
Patent Application Number
16810319
0
Date Filed
March 5, 2020
0
Patent Citations
US Patent 7829673 Antibodies against CD38 for treatment of multiple myeloma
0
US Patent 7928203 Chimeric, humanized, or human antibody 2A4
0
US Patent 8105594 Methods for amyloid removal using anti-amyloid antibodies
0
US Patent 8263746 Anti-CD38 human antibodies and uses thereof
0
US Patent 9249226 Antibodies against human CD38
0
US Patent 9364542 Protein formulations containing amino acids
0
US Patent 9884020 Antibody formulations and methods for treating AL amyloidosis
0
US Patent 10046050 Targeting immunotherapy for amyloidosis
0
US Patent 10766965 Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies
0
Patent Primary Examiner
Olga N. Chernyshev
0
CPC Code
C07K 2317/24
0
C07K 16/18
0
A61K 9/0019
0
A61B 5/0205
0
Find more entities like US Patent 11692024 Methods of treating AL amyloidosis
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Company
Home
Press & Media
Blog
Careers
WE'RE HIRING
Products
Knowledge Graph
Query Tool
Data Requests
Knowledge Storage
API
Pricing
Enterprise
ChatGPT Plugin
Legal
Terms of Service
Enterprise Terms of Service
Privacy Policy
Help
Help center
API Documentation
Contact Us
By using this site, you agree to our
Terms of Service
.
SUBSCRIBE